Overview
Metastatic malignant neoplasms involving the pelvic peritoneum represent a challenging clinical scenario, often associated with advanced stages of gynecologic and gastrointestinal cancers. These conditions are characterized by high recurrence rates, with over 22,000 new cases annually in the U.S., and a significant burden of symptoms that profoundly impact quality of life (QoL). The management of these patients requires a multidisciplinary approach, integrating oncology, palliative care, and supportive therapies to address both disease progression and symptom management effectively. Understanding the epidemiology, clinical presentation, and optimal management strategies is crucial for improving patient outcomes and caregiver support.
Epidemiology
The epidemiology of metastatic malignant neoplasms to the pelvic peritoneum underscores the significant clinical burden and variability in patient demographics and outcomes. In the U.S., the annual incidence exceeds 22,000 cases, with a notable recurrence rate of 75%, highlighting the persistent nature of these malignancies (PMID:23369942). Geographic and demographic factors also play a role; studies from Nova Scotia indicate that younger patients (20-54 years, OR 4.9; 55-64 years, OR 3.4; 65-74 years, OR 3.1) and those residing in Halifax County (OR 19.2) are more frequently referred to palliative care programs compared to older patients and those living elsewhere (PMID:9676544). This suggests potential disparities in access to or awareness of palliative care services across different populations. Additionally, among gynecologic oncology inpatients, only 24% (82 patients) received palliative care consultations, indicating a significant gap in integrating palliative care early in the disease trajectory (PMID:24594073). These findings emphasize the need for targeted interventions to ensure timely palliative care referrals, particularly in vulnerable populations.
Clinical Presentation
Patients with metastatic malignant neoplasms involving the pelvic peritoneum often present with a constellation of severe symptoms that significantly impair their quality of life. Peritoneal carcinomatosis commonly manifests as malignant bowel obstruction (MBO), affecting approximately 25–50% of ovarian cancer patients, necessitating aggressive symptom management strategies (PMID:23369942). Common clinical presentations include intractable pain, nausea, vomiting, obstipation, and recurrent ascites, which can lead to complications such as bowel, lymphatic, or ureteral obstructions (PMID:38954989). These symptoms not only diminish physical comfort but also contribute to psychological distress, including anxiety and feelings of powerlessness (PMID:38954989). Patients aged 65-84 years (OR 1.4) and those 85 years and older (OR 1.8) are more likely to be referred late to palliative care, often coinciding with advanced disease stages and poorer prognoses (PMID:9676544). The severity of symptoms often drives the need for palliative interventions such as percutaneous endoscopic gastrostomy (PEG) tube placement, palliative exenteration, and radiation therapy, underscoring the multifaceted approach required in managing these patients (PMID:8726186).
Diagnosis
Diagnosing metastatic malignant neoplasms in the pelvic peritoneum typically involves a combination of clinical assessment, biochemical markers, and advanced imaging techniques. Clinical examination remains foundational, providing initial clues about the extent and nature of the disease. Biochemical markers, such as CA-125 in ovarian cancer, can aid in diagnosis and monitoring disease progression (PMID:27169699). Imaging modalities, including computed tomography (CT) scans and magnetic resonance imaging (MRI), play a crucial role in delineating the extent of peritoneal involvement and identifying complications such as bowel obstructions or ascites accumulation (PMID:8726186). These diagnostic tools help in staging the disease and guiding treatment decisions, although their interpretation should be contextualized within the broader clinical picture to ensure accurate diagnosis and appropriate management planning.
Differential Diagnosis
Differentiating metastatic malignant neoplasms from other conditions affecting the pelvic peritoneum is essential for accurate diagnosis and tailored treatment. Conditions such as inflammatory bowel disease, endometriosis, and primary peritoneal malignancies can mimic the clinical presentation of metastatic disease (PMID:38954989). The Ottawa Decision Support Framework emphasizes the importance of considering patients' values, goals, and preferences in the decision-making process, ensuring that differential diagnoses are approached in a patient-centered manner (PMID:38954989). For instance, head and neck cancers are positively associated with palliative care program (PCP) referrals (OR 5.4), whereas hematological (OR 0.2), lymph node (OR 0.3), and lung (OR 0.6) cancers show negative associations, highlighting the need for nuanced clinical judgment based on primary tumor type (PMID:9676544). Comprehensive evaluation, including thorough history-taking, physical examination, and targeted diagnostic workups, is crucial to rule out other potential causes and guide appropriate interventions.
Management
The management of metastatic malignant neoplasms involving the pelvic peritoneum is multifaceted, focusing on symptom control, quality of life improvement, and supportive care alongside disease-directed therapies. Palliative care plays a pivotal role, aiming to alleviate symptoms such as pain, nausea, obstipation, and psychological distress (PMID:38954989). Interventions like percutaneous endoscopic gastrostomy (PEG) tube placement and palliative exenteration are employed to manage symptoms such as bowel obstruction and bleeding, with palliative exenteration offering symptom relief in approximately 79% of patients, albeit with significant postoperative morbidity (53.6%) and mortality (6.3%) (PMID:31255441). Chemotherapy, radiation therapy, and hormonal treatments are often utilized, tailored to the specific malignancy and patient tolerance. The BOLSTER intervention, a nurse-led telehealth program, has shown promise in enhancing patient and caregiver quality of life through longitudinal support and tailored educational tools (PMID:38851039). Despite the benefits, challenges such as managing complex care needs post-procedure and addressing caregiver burden remain critical areas requiring ongoing support and intervention (PMID:38954989).
Symptom Management
Effective symptom management is central to improving the quality of life for patients with metastatic malignant neoplasms in the pelvic peritoneum. Pain, nausea, vomiting, obstipation, and psychological distress are prevalent and often debilitating (PMID:38954989). Palliative radiation therapy has been shown to increase the odds of palliative care consultation (OR 1.8), indicating its role not only in symptom relief but also in facilitating timely palliative care integration (PMID:9676544). Pharmacological interventions, including opioids for pain management and antiemetics for nausea, are essential, but non-pharmacological approaches such as psychological support and symptom-focused counseling are equally important (PMID:35123817). The BOLSTER intervention exemplifies the potential of structured support programs in enhancing patient self-efficacy and reducing caregiver burden, thereby improving overall QoL (PMID:38851039).
Palliative Procedures
Palliative procedures, such as palliative pelvic exenteration (PPE) and percutaneous endoscopic gastrostomy (PEG) tube placement, are critical for managing severe symptoms and improving patient comfort. PPE, while offering significant symptom relief in selected patients, carries substantial risks, including postoperative morbidity (53.6%) and mortality (6.3%) (PMID:31255441). These procedures are recommended only after comprehensive multidisciplinary discussions, ensuring that the potential benefits outweigh the risks (PMID:35123817). Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown promise in managing neoplastic ascites, with studies indicating improved free intervals between ascites drainages and reduced drained volumes, alongside enhanced quality of life measures (PMID:27169699). However, the decision to proceed with such interventions should be individualized, considering factors like patient performance status, disease extent, and overall prognosis (PMID:25778323).
Multidisciplinary Care
Integrating palliative care early in the disease trajectory is strongly supported by evidence showing improved outcomes, including prolonged survival and reduced symptom burden (PMID:30934082). The Society of Gynecologic Oncology, National Comprehensive Cancer Network, and American Society of Clinical Oncology endorse early palliative care integration as part of standard oncology care (PMID:30683263). Public hospitals often face challenges in resource allocation but demonstrate comparable improvements in pain and nausea management, though they lag in addressing anxiety and dyspnea (PMID:35085457). Team-based care models, incorporating oncology, palliative care, and supportive services, are crucial for addressing the multifaceted needs of these patients (PMID:31849272). Despite strong recommendations, only about half of surveyed physicians feel adequately resourced to deliver early palliative care, underscoring the need for enhanced training and support systems (PMID:31849272).
Complications
Patients undergoing palliative interventions for metastatic malignant neoplasms in the pelvic peritoneum face significant complications that can impact both their physical and psychological well-being. Surgical procedures like palliative pelvic exenteration are associated with substantial morbidity, including perineal wound complications and prolonged recovery times, which can exacerbate patient distress and caregiver burden (PMID:35123817). Postoperative complications such as infections, bleeding, and bowel dysfunction are common, necessitating vigilant monitoring and multidisciplinary management (PMID:31255441). Non-surgical interventions, such as percutaneous endoscopic gastrostomy (PEG) tube placement, while generally safe, require careful follow-up to manage potential complications like tube displacement or infection (PMID:23369942). Psychological impacts, including anxiety and feelings of powerlessness, are prevalent among patients and caregivers, emphasizing the importance of comprehensive supportive care strategies (PMID:38954989).
Prognosis & Follow-up
The prognosis for patients with metastatic malignant neoplasms involving the pelvic peritoneum is generally poor, with median survival times often measured in months rather than years. Palliative pelvic exenteration, while offering symptom relief in a median of 79% of patients, is associated with significant postoperative morbidity and mortality, with a median overall survival of approximately 14 months (PMID:31255441). Early palliative care integration is linked to better quality of life and caregiver adjustment, aligning treatments with patients' values and preferences (PMID:38954989). However, the implementation of goal-concordant care in decision-making processes remains underexplored but is crucial for optimizing patient outcomes (PMID:38954989). Regular follow-up is essential to monitor symptom progression, adjust treatments, and provide ongoing psychological and social support. Public hospitals, despite facing resource constraints, often conduct more patient visits and clarify code status more frequently, indicating a proactive approach to end-of-life care (PMID:35085457). Nonetheless, the overall prognosis underscores the need for compassionate, holistic care that addresses both physical and emotional needs.
Special Populations
Special populations, including those with gynecologic and gastrointestinal cancers, present unique challenges and considerations in the management of metastatic malignant neoplasms involving the pelvic peritoneum. Initially focused on gynecologic cancers, interventions like the BOLSTER telehealth program have expanded to include patients with gastrointestinal malignancies, highlighting the broader applicability of supportive care strategies (PMID:38851039). Demographic disparities are evident, with public hospital patients being younger, more racially diverse, and less likely to speak English compared to those in private hospitals (PMID:35085457). These differences can influence access to care and the types of interventions received. Additionally, primary care providers often advocate for renaming palliative care to "supportive care" to enhance patient comfort and engagement in early palliative care referrals (PMID:31849272). The Brazilian experience underscores the importance of humanization efforts, specialized wards, and multidisciplinary teams in improving palliative care delivery for terminally ill patients (PMID:24998116). Tailored interventions and culturally sensitive approaches are essential to address the diverse needs of these special populations effectively.
Key Recommendations
These recommendations aim to optimize patient care, improve QoL, and support both patients and their caregivers through the complex journey of managing metastatic malignant neoplasms in the pelvic peritoneum.
References
1 Wall JA, Pozzar RA, Enzinger AC, Tavormina A, Howard C, Matulonis UA et al.. Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis. Gynecologic oncology 2024. link 2 Pozzar RA, Enzinger AC, Howard C, Tavormina A, Matulonis UA, Campos S et al.. Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial. Gynecologic oncology 2024. link 3 Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM et al.. Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer. Gynecologic oncology 2013. link 4 Johnston GM, Gibbons L, Burge FI, Dewar RA, Cummings I, Levy IG. Identifying potential need for cancer palliation in Nova Scotia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 1998. link 5 Chang KH, Solomon MJ. The role of surgery in the palliation of advanced pelvic malignancy. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2022. link 6 van Zyl C, O'Riordan DL, Kerr KM, Harris HA. Doing More with the Same: Comparing Public and Private Hospital Palliative Care within California. Journal of palliative medicine 2022. link 7 Sorensen A, Le LW, Swami N, Hannon B, Krzyzanowska MK, Wentlandt K et al.. Readiness for delivering early palliative care: A survey of primary care and specialised physicians. Palliative medicine 2020. link 8 . Palliative pelvic exenteration: A systematic review of patient-centered outcomes. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019. link 9 Reynolds EE, Buss MK, Schlechter BL, Tess A. Would You Refer This Patient With Cancer to a Palliative Care Specialist?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals of internal medicine 2019. link 10 Mullen MM, Cripe JC, Thaker PH. Palliative Care in Gynecologic Oncology. Obstetrics and gynecology clinics of North America 2019. link 11 Orgiano L, Pani F, Astara G, Madeddu C, Marini S, Manca A et al.. The role of "closed abdomen" hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016. link 12 Spiliotis J, Halkia E, Rogdakis A, Kastrinaki K, Lianos E, Efstathiou E. Clinical history of patients with peritoneal carcinomatosis exluded from cytoreductive surgery & HIPEC. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2015. link 13 Garcia JB, Rodrigues RF, Lima SF. Structuring a palliative care service in Brazil: experience report. Brazilian journal of anesthesiology (Elsevier) 2014. link 14 Lefkowits C, Binstock AB, Courtney-Brooks M, Teuteberg WG, Leahy J, Sukumvanich P et al.. Predictors of palliative care consultation on an inpatient gynecologic oncology service: are we following ASCO recommendations?. Gynecologic oncology 2014. link 15 Wanebo HJ, Chung MA, Levy AI, Turk PS, Vezeridis MP, Belliveau JF. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Annals of surgical oncology 1996. link 16 Finlayson CA, Eisenberg BL. Palliative pelvic exenteration: patient selection and results. Oncology (Williston Park, N.Y.) 1996. link 17 Woodhouse CR, Plail RO, Schlesinger PE, Shepherd JE, Hendry WF, Breach NM. Exenteration as palliation for patients with advanced pelvic malignancy. British journal of urology 1995. link
17 papers cited of 19 indexed.